Melan-A/Mart-1 expression in various melanocytic lesions and in non- melanocytic soft tissue tumours

Histopathology

Volumn 34, Issue 6, 1999, Pages 517-525

  Orosz, Z ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

Author keywords

Carcinoid; Melan A Mart 1; Melanocytic lesions; Soft tissue sarcomas

Indexed keywords

GENE PRODUCT; PROTEIN HMB 45; PROTEIN MART 1; PROTEIN MELAN A; PROTEIN S 100; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EPITHELIOID CELL; GASTROINTESTINAL TUMOR; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MELANOCYTE; MELANOMA; PRIORITY JOURNAL; SOFT TISSUE SARCOMA; SPINDLE CELL;

ANTIGENS, NEOPLASM; CARCINOID TUMOR; CARCINOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM PROTEINS; S100 PROTEINS; SARCOMA; SKIN NEOPLASMS; SOFT TISSUE NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0033023185     PISSN: 03090167     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2559.1999.00679.x     Document Type: Article

References (16)

1. 1. Coulie PG, Brichard V, Van Pel A et al. A new gene coding for a differentiation antigen recognised by autologous cytotoxic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 1994; 180; 35-42.
2. 2. Kawakami Y, Eliyahu S, Delgado CH et al. Cloning the gene coding for shared human melanoma antigen recognised by autologous T cells infiltrating into tumor. Proc. Natl. Acad. Sci. USA 1994; 91; 3515-3519.
3. 3. Chen Y-T, Stockert E, Jungbluth A et al. Serological analysis of Melan-A (Mart-1), a melanocyte specific protein homogenously expressed in human melanomas. Proc. Natl. Acad. Sci. USA 1996; 93; 5915-5919.
4. 4. Marincola P, Hijazi YM, Fetsch PA et al. Analysis of the melanoma associated antigens MART-1 and GP-100 in metastatic melanoma cell lines and in situ lesions. J. Immunother. 1996; 19; 192-205.
5. 5. Beaty MW, Fetsch PA, Wilder AM, Marincola F, Abati A. Effusion cytology of malignant melanoma. A morphologic and immunocytochemical analysis including application of the MART-1 antibody. Cancer (Cancer Cytopathol.) 1997; 81; 57-63.
6. 6. Fetsch PA, Cormier J, Hijazi YM. Immunocytochemical detection of MART-1 in fresh and paraffin embedded-melanomas. J. Immunother. 1997; 20; 60-64.
7. 7. Blessing K, Sanders DSA, Grant JJH. Comparison of immunohistochemical staining of the novel antibody melan-A with S100 protein and HMB-45 in malignant melanoma and melanoma variants. Histopathology 1998; 32; 139-146.
8. 8. Busam KJ, Chen Y-T, Old LJ et al. Expression of Melan-A (MART1) in benign melanocytic nevi and primary cutaneous melanoma. Am. J. Surg. Pathol. 1998; 22; 976-982.
9. 9. Kahn HJ, Marks A, Thom H, Baumal R. Role of antibody to S-100 protein in diagnostic pathology. Am. J. Clin. Pathol. 1983; 79; 341-379.
10. 10. Nakajima T, Watanabe S, Sato Y, Kameya T, Hirota T, Shimosato Y. Immunoperoxidase study of S-100 protein distribution in normal and neoplastic tissue. Am. J. Surg. Pathol. 1982; 6; 715-727.
11. 11. Skelton HG 3d, Smith KJ, Barrett TL, Lupton G, Graham JH. HMB-45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation. Am. J. Dermatopathol. 1991; 13; 543-550.
12. 12. Pea M, Bonetti F, Zamboni G et al. Melanocyte-marker-HMB-45 is regularly expressed in angiomyolipoma of the kidney. Pathology 1991; 23; 185-188.
13. 13. Hoon V, Thung SN, Kaneko M, Unger PD. HMB-45 reactivity in renal angiomyolipoma and lymphangioleiomyomatosis. Arch. Pathol. Lab. Med. 1994; 118; 732-734.
14. 14. Gal AA, Koss MN, Hochholzer L, Chejfec G. An immunohistochemical study of benign clear cell ('sugar') tumor of the lung. Arch. Pathol. Lab. Med. 1991; 115; 1034-1038.
15. 15. Fetsch PA, Fetsch JF, Marincola FM, Travis W, Batts KP, Abati A. Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor. Mod. Pathol. 1998; 11; 699-703.
16. 16. Yates AJ, Banerjee SS, Bishop PW, Graham KE. HMB-45 in non melanocytic tumours. Histopathology 1993; 23; 477-479.